Journal of Commercial Biotechnology — February 2011 issue now available

The February 2011 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:

Volume 17, Issue 1

Editorial

Applying design thinking to biotechnology	PDF
Yali Friedman

Commentary

Building biotechnology by design: An entrepreneur’s perspective	PDF
Arthur A Boni

Building biotechnology by design: Role of biotechnology in development	PDF
Patrick Nef

Articles

Pricing biologics: Issues, strategic priorities and a conceptual model	PDF
Sanjay K Rao

Revitalizing portfolio decision-making at Merck Serono S.A. – Geneva	PDF
Vincent Aurentz, Bernhard Kirschbaum, Markus Thunecke

Global consensus – Need of the hour for genetically modified organisms (GMO) labeling	PDF
Jagadeesan Premanandh

Beyond investment: Advancing the biotechnology sector in the countries of the Gulf Cooperation Council (GCC)	PDF
Leonard Lerer, Brett Bowman

Case Study

Repurposing of the epidermal growth factor	PDF
Ernesto L Mola, José A Buxadó, Luis Herrera

Biotechnology commercialization: A case study from Central and Eastern Europe	PDF
Dana Ukropcova, Ernest Sturdik

The developments in the business models of biotechnology in the Central and Eastern European countries: The example of Estonia	PDF
Margit Suurna

Legal and Regulatory Updates

EU Legal and Regulatory Update	PDF
Gerry Kamstra

0 Comments/

0 Likes

/0 Tweets/in General Biotechnology

January 5, 2011

05 Jan 2011

Take my course on Biotechnology Management at the NIH

I will be teaching Biotechnology Management (TECH 566) again this spring at the National Institutes of Health Foundation for Advanced Education in the Sciences. The focus of this course is on learning the skills necessary to succeed in the biotechnology industry. Classes are comprised of a combination of lectures based on my textbook, Building Biotechnology, and guest lectures from local entrepreneurs, financiers, and biotechnology company management.

Classes start on January 25th, and are held on Tuesday evenings in the NIH Office of Technology Transfer offices. For more details, see TECH 566 in the FAES course catalog.

1 Comment/

0 Likes

/2 Tweets/in General Biotechnology

January 3, 2011

03 Jan 2011

Drug Patent Expirations in January 2011

*Drugs may be covered by multiple patents

Tradename	Applicant	Generic Name	Patent Number	Patent Expiration
VITRAVENE PRESERVATIVE FREE	Novartis	fomivirsen sodium	5,276,019	Jan 4, 2011
ELIGARD	Tolmar Therap	leuprolide acetate	5,278,201	Jan 11, 2011
ULTIVA	Bioniche Teoranta	remifentanil hydrochloride	5,019,583*PED	Jan 12, 2011
XELODA	Hoffmann La Roche	capecitabine	4,966,891	Jan 13, 2011
DUETACT	Takeda Global	glimepiride; pioglitazone hydrochloride	4,687,777	Jan 17, 2011
ACTOS	Takeda Pharms Na	pioglitazone hydrochloride	4,687,777	Jan 17, 2011
ACTOPLUS MET	Takeda Global	metformin hydrochloride; pioglitazone hydrochloride	4,687,777	Jan 17, 2011
ACTOPLUS MET XR	Takeda Global	metformin hydrochloride; pioglitazone hydrochloride	4,687,777	Jan 17, 2011
PROTONIX IV	Wyeth Pharms Inc	pantoprazole sodium	4,758,579*PED	Jan 19, 2011
PROTONIX	Wyeth Pharms Inc	pantoprazole sodium	4,758,579*PED	Jan 19, 2011
EMEND	Merck	aprepitant	5,145,684	Jan 25, 2011
MEGACE ES	Par Pharm	megestrol acetate	5,145,684	Jan 25, 2011
TRICOR	Abbott	fenofibrate	5,145,684	Jan 25, 2011
VFEND	Pfizer	voriconazole	5,773,443	Jan 25, 2011
BAYCOL	Bayer Pharms	cerivastatin sodium	5,177,080	Jan 26, 2011